Disclosed in the present invention is a handover method for satellite base stations of a low earth orbit satellite mobile network. The method comprises: a source satellite base station being connected to a UE sending a handover request to a target satellite base station; upon receiving the handover request, the target satellite base station performing handover preparation, and sending handover acknowledgement to the source satellite base station, and the source satellite base station receiving the handover acknowledgement; the source satellite base station notifying the UE connected thereto of a handover decision, the UE disconnecting from the source satellite base station and establishing a new RRC connection with the target satellite base station; and the source satellite base station and the target satellite base station transmitting synchronous data. The handover preparation comprises pre-allocating channel resources. By means of a rapid handover method introduced into a satellite mobile network, the present invention calculates the position of a satellite on the basis of ephemeris, so as to predict the occurrence of handover on a user side, thereby significantly reducing handover latency for users in this scenario.
Provided in the present invention is a parameter-efficient large-language fine-tuning federated learning framework, comprising the following steps: performing modeling on LoRA adapters of different edge clouds; since different weights exhibit different average performances on the LoRA adapters, using singular values to quantify the importance of the weights, and therefore, before each round of independent training of the LoRA adapters using N edge clouds, using a matrix singular value to decompose a BA matrix in the LoRA adapter for each trainable weight; configuring heterogeneous LoRA adapters on the basis of the importance of the weights; and using different numbers of quantization bits to quantize a pre-trained model, and performing high-precision inverse quantization on the pre-trained model only when matrix multiplication is executed, wherein the pre-trained model is quantized to the maximum number of quantization bits on the basis of the memory budget of the edge clouds. The present invention has the following beneficial effects: the present invention determines the optimal fine-tuning model structure, thereby improving the performance of LLM fine-tuning, and adapts to heterogeneous and resource-constrained edge clouds.
Provided are an ionizable lipid, a screening method therefor and application thereof. The molecular structure of the ionizable lipid can be predicted on the basis of a model algorithm, such that fundamental properties such as in-vivo mRNA delivery efficiency and apparent pKa can be predicted, and thus the present invention can be applied to formulation screening of mRNA lipid nanoparticles. Moreover, a physiologically-based pharmacokinetic (PBPK) model is developed for calculating a rate constant for a key step in the pharmacokinetics of lipid nanoparticles. The method and the model provide guidance for the research on and development of lipid nanoparticles, thereby facilitating the rapid development of mRNA-LNP drugs. By using a model simulation technique, a variety of new ionizable lipids, which can be used for an mRNA-LNP delivery system, can be obtained by means of screening, and the high delivery efficiency thereof has also been effectively verified.
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
4.
HUMAN BODY STRUCTURAL MATERIAL TYPE XX COLLAGEN AND BIOSYNTHESIS METHOD THEREFOR
Provided are a human body structural material type XX collagen and a biosynthesis method therefor. The collagen comprises an amino acid sequence as shown in SEQ ID NO: 2 or a variant amino acid sequence obtained by mutation of the amino acid sequence as shown in SEQ ID NO: 2, wherein the variant amino acid sequence retains the function of the amino acid sequence as shown in SEQ ID NO: 2. The collagen can promote cell adhesion and has a triple helix structure.
Methods of producing a plurality of folded MHC-peptide complexes and identifying a pool of peptides suitable for cancer diagnosis. The methods of producing a plurality of folded MHC-peptide complexes comprise: a) adding a plurality of distinct peptides into a refolding buffer, wherein the concentration of the plurality of distinct peptides in the refolding buffer is at least about 0.01 mg/mL; and b) adding an MHC molecule into the refolding buffer and incubating for at least one day; thereby producing a plurality of folded MHC-peptide complexes.
The present invention provides a multi-modal model construction method and system for predicting the efficacy of sorafenib in hepatocellular carcinoma. The method comprises: step 1, collecting clinical information of a target patient, and generating a whole slide image; step 2, preprocessing clinical data, and retaining clinical features as input for a multi-modal deep learning model; step 3, preprocessing the whole slide image; step 4, constructing an image model, acquiring patch-level scores of the pathological image on the basis of the preprocessed image and by using different aggregation algorithms, and predicting the score of the whole pathological image to obtain best model features; step 5, constructing a multi-modal model, performing modal fusion on the best model features and the clinical features, and outputting an image-level or patient-level prediction result; and step 6, testing and evaluating the model. The present invention achieves bimodal input of a pathological image and clinical information, fully utilizes the complementarity of the two types of modal data, and thus improves prediction accuracy.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A multispecific antibody or an antigen-binding molecule thereof, a homodimer thereof, a nucleic acid molecule encoding the multispecific antibody or the antigen-binding molecule thereof, a vector comprising the nucleic acid molecule, a host cell comprising the vector, a recombinant protein or immunoconjugate comprising the multispecific antibody or the antigen-binding molecule thereof, a use thereof in the preparation of a medicament for treating or preventing respiratory tract infections caused by viruses or in the preparation of a medicament for treating or preventing respiratory tract inflammation or dermatitis, and in a detection product. The multispecific antibody or the antigen-binding molecule thereof has excellent broad-spectrum neutralizing capability for coronaviruses and significant neutralizing capacity for coronavirus mutant strains, especially a variety of SARS-CoV-2 coronavirus mutant strains including Omicron subvariants BQ.1.1, XBB.1.5, XBB.1.16, EG.5, BA.2.86, and JN.1. The multispecific antibody or the antigen-binding molecule thereof can not only treat or prevent respiratory tract infection symptoms caused by viruses but also significantly relieve respiratory tract inflammation responses. The multispecific antibody or the antigen-binding molecule thereof has a good therapeutic effect on inflammatory diseases such as rhinitis, asthma, and dermatitis and has good clinical application prospects in the future.
A semiconductor device, including at least one organic semiconductor (OSC) polymer and at least one photosensitizer, such that the at least one OSC polymer is a diketopyrrolopyrrole-fused thiophene polymeric material, and the fused thiophene is beta-substituted.
G03F 7/00 - Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printed surfacesMaterials therefor, e.g. comprising photoresistsApparatus specially adapted therefor
G03F 7/038 - Macromolecular compounds which are rendered insoluble or differentially wettable
G03F 7/039 - Macromolecular compounds which are photodegradable, e.g. positive electron resists
The present invention provides a linker, an antibody-drug conjugate, and a preparation method therefor. The drug linker of the present invention has good solubility, and can greatly improve the water solubility of existing small molecule compounds and improve the stability and uniformity of the conjugate after being conjugated to an antibody.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A microvascular flow ultrasonic imaging method and system are provided. The method comprises: includes constructing a combined sequence having a linear imaging sequence and a nonlinear imaging sequence; transmitting the combined sequence to an imaging area and acquiring multiple groups of echo signals within a preset time period to form an echo signal group sequence; sequentially carrying out nonlinear filtering processing and beamforming on each group of echo signals in the echo signal group sequence to obtain a corresponding nonlinear ultrasound image sequence; identifying microbubbles in each frame of image of the nonlinear ultrasound image sequence frame by frame, and tracking a trajectory of the microbubbles according to identifying and positioning results, a microbubble trajectory being determined by identifying and positioning results of microbubbles in continuous N frames of images in the image sequence; and reconstructing and obtaining a super-resolution microvascular flow image based on the tracked microbubble trajectory.
A two-dimensional (2D) Dirac material-based charge super injection memory, which includes a substrate, a gate electrode provided on the substrate, a blocking layer covering the substrate electrode and the gate electrode, a charge storage layer provided on the blocking layer, a tunneling layer provided on the charge storage layer, a channel provided on the tunneling layer, and a source electrode and a drain electrode both provided on the channel. The channel material is a 2D Dirac material with a tapered band structure, and the electron affinity of the channel material is greater than that of the tunneling layer material. The electron affinity of the charge storage layer material exceeds those of both the tunneling layer material and the blocking layer material, and the bandgap of the charge storage layer material is smaller than those of the tunneling layer material and the blocking layer material.
H10D 62/83 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials being Group IV materials, e.g. B-doped Si or undoped Ge
SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (China)
FUDAN UNIVERSITY (China)
Inventor
Cheng, Zhen
Tian, Mei
Tao, Ji
Qu, Chunrong
Abstract
The present invention provides a compound as represented by formula I or a pharmaceutically acceptable salt, precursor compound, isotope compound, stereoisomer or tautomer thereof. The compound has high affinity and strong targeting specificity for melanoma, low non-specific uptake in livers and kidneys, and a high tumor/non-tumor ratio. In addition, the probe precursor of the present invention can selectively chelate different radioactive diagnostic or therapeutic nuclides, and is used in single-photon emission computed tomography for early diagnosis of major diseases such as malignant tumors and Parkinson's disease, guiding the selection of a treatment regimen, efficacy monitoring, and radioactive therapy. The compound is simple to synthesize, has easily available raw materials and good stability, and can be promoted and applied as a novel melanoma-targeted radiopharmaceutical.
C07F 13/00 - Compounds containing elements of Groups 7 or 17 of the Periodic Table
C07C 323/25 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
An ultrafast two-dimensional (2D) flash memory device based on Fowler-Nordheim (FN) tunneling, including a substrate, a gate electrode, a blocking layer, a floating gate, a tunneling layer, a 2D channel, a source electrode and a drain electrode. The gate electrode is provided at a middle of the substrate. The blocking layer is configured to cover the gate electrode and the substrate. The floating gate is provided on the blocking layer, and is entirely encompassed within a coverage area of the gate electrode. The tunneling layer is configured to cover the floating gate and the blocking layer. The 2D channel is provided on the tunneling layer, and is entirely encompassed within a coverage area of the floating gate. The source electrode and the drain electrode are configured to partially overlap with the 2D channel. A method for preparing such device is also provided.
H10D 30/47 - FETs having zero-dimensional [0D], one-dimensional [1D] or two-dimensional [2D] charge carrier gas channels having 2D charge carrier gas channels, e.g. nanoribbon FETs or high electron mobility transistors [HEMT]
14.
TWO-DIMENSIONAL SEMICONDUCTOR MATERIAL-BASED CHARGE SUPER-INJECTION MEMORY AND PREPARATION THEREOF
A two-dimensional semiconductor material-based charge super-injection memory, including a substrate, a gate electrode, a blocking layer, a charge-trapping layer, a tunneling layer, a two-dimensional semiconductor channel layer, a drain electrode and a source electrode. The gate electrode is provided above the substrate. The blocking layer is configured to cover the gate electrode and the substrate. The charge-trapping layer is provided on the blocking layer. The tunneling layer is provided on the charge-trapping layer. The two-dimensional semiconductor channel layer is provided on the tunneling layer. The two-dimensional semiconductor channel layer is entirely encompassed within a coverage area of the gate electrode and a coverage area of the tunneling layer. The drain electrode and the source electrode are each partially overlapped with the two-dimensional semiconductor channel layer. A fabrication method of such charge super-injection memory is also provided.
H10D 30/47 - FETs having zero-dimensional [0D], one-dimensional [1D] or two-dimensional [2D] charge carrier gas channels having 2D charge carrier gas channels, e.g. nanoribbon FETs or high electron mobility transistors [HEMT]
H10D 62/10 - Shapes, relative sizes or dispositions of the regions of the semiconductor bodiesShapes of the semiconductor bodies
H10D 62/80 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials
H10D 64/62 - Electrodes ohmically coupled to a semiconductor
H10D 64/66 - Electrodes having a conductor capacitively coupled to a semiconductor by an insulator, e.g. MIS electrodes
H10D 64/68 - Electrodes having a conductor capacitively coupled to a semiconductor by an insulator, e.g. MIS electrodes characterised by the insulator, e.g. by the gate insulator
15.
MEMORY CHIP BASED ON TWO-DIMENSIONAL (2D) FLASH MEMORIES WITH COMPLEMENTARY METAL-OXIDE-SEMICONDUCTOR (CMOS) TECHNOLOGY AND ITS FABRICATION METHOD
A memory chip based on two-dimensional (2D) flash memories with complementary metal oxide semiconductor (CMOS) technology, including a substrate structure with a memory peripheral circuit and a 2D material flash memory array. The substrate structure is fabricated using CMOS technology, and the flash memory array is constructed from 2D material-based flash memories. The substrate is prepared by a standard CMOS process and includes different doping types of silicon on the substrate, metal wires for interconnections between devices, and dielectric layers for isolation. The flash memory array has a multi-layer structure.
H10D 30/47 - FETs having zero-dimensional [0D], one-dimensional [1D] or two-dimensional [2D] charge carrier gas channels having 2D charge carrier gas channels, e.g. nanoribbon FETs or high electron mobility transistors [HEMT]
16.
SYSTEMS AND METHODS FOR IDENTIFYING MICROBIOMIC TREATMENT FOR HEREDITARY AND METABOLIC DISEASES
Disclosed herein are methods and systems ofscreening for microbiomics treatments for hereditary diseases or metabolic diseases using high-throughput nematode models. Genetically modified bacteria with therapeutic potential in treating certain hereditary diseases or metabolic diseases, compositions comprising such bacteria, as well as methods of uses such bacteria are also disclosed herein.
Provided in the present invention are a 2-aminothiazole compound derivative and the use thereof. The compound has a chemical structure of general formula (I) as shown in the following formula. The compound derivative provided in the present invention has an inhibitory activity against dihydroorotate dehydrogenase (DHODH), and is expected to be used in the preparation of a drug for preventing and/or treating diseases related to DHODH.
C07D 277/60 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A method for preparing chondroitin with a controllable molecular weight. The chondroitin is obtained by taking an initiator as an initial polymerization substrate; sequentially bonding n comonomers at a non-reducing end of the initiator, wherein the comonomers are formed from acetylated hexosamine and uronic acid by means of a glycosidic bond; and the comonomers and the initiator being polymerized under the action of catalysis of a polymerase to form a polysaccharide with a certain molecular weight, namely the chondroitin. The chondroitin preparation technology can prepare chondroitin for which the molecular weight varies in a linear manner, the controllable molecular weight range is wide, and the molecular weight distribution is narrow. The molecular weight range can include 10,000-5,000,000; 100,000-4,000,000; 250,000-3,000,000; 350,000-2,000,000; 500,000-1,000,000; 20,000-300,000; 1,000-70,000; 70,000-300,000; 350,000-660,000; 380,000-900,000.
A cationic lipid compound, a composition comprising the cationic lipid compound, and a use. A compound is as represented by general formula (I). Also provided are a cationic lipid compound comprising the compound, or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof. The present application also relates to an immune cell-targeted lipid nanoparticle, and a screening method therefor and a use thereof. Specifically disclosed is a use of the compound of formula (I), or the pharmaceutically acceptable salt, prodrug, or stereoisomer thereof in targeting immune cells, and also disclosed are a method for in vitro screening of lipid nanoparticles and a method for screening lipid nanoparticles suitable for delivering mRNA to various immune cells in vivo.
C07C 229/16 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
C07C 237/10 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
Provided are a pharmaceutical composition for preventing and/or treating neurodegenerative diseases and use thereof. The pharmaceutical composition comprises rivastigmine, liraglutide, and derivatives thereof; the pharmaceutical composition further comprises a sustained-release system, the sustained-release system can interact with the rivastigmine, the liraglutide, and the derivatives thereof to form a copolymer that enables sustained drug release, and the sustained-release system is a triblock hydrogel sustained-release system. The combination of the liraglutide and the rivastigmine can ameliorate the learning and memory impairments associated with Alzheimer's disease, with the effect superior to monotherapy and exhibiting a synergistic effect.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
An ammonia-driven hydrogel dehydration-desalination method is provided. The method includes the following steps: a hydrogel soaking step: soaking a hydrogel in salt water; and an ammonia dehydration step: placing the hydrogel after water absorption in a closed container, and introducing ammonia for making the ammonia dissolved on a surface of the hydrogel to produce a high osmotic pressure, so as to promote the permeation of water molecules out of the hydrogel and to obtain produced water
Use of 6-phosphogluconic acid and a derivative thereof in preparing a medicament for preventing or treating glycometabolism disorder diseases. The 6-phosphogluconic acid and the derivative thereof are a type of cell glycometabolism regulators and diabetes treatment agents, have a remarkable regulation effect on islet alpha cells, and can be further prepared into a medicament for preventing or treating diabetes and other glycometabolism disorder diseases.
INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES (China)
Inventor
Lu, Lu
Zhu, Yun
Yang, Xia
Jiang, Shibo
Hua, Chen
Wang, Qian
Xu, Wei
Sun, Fei
Wang, Jian
Wang, Ying
Abstract
Provided is a method for biosynthesis of a human structural material type XVII collagen. The collagen comprises the amino acid sequence shown in SEQ ID NO: 2 or a variant amino acid sequence after mutation of the amino acid sequence. The variant amino acid sequence retains the function of the amino acid sequence as shown in SEQ ID NO: 2. The collagen can promote cell adhesion and has a triple helix structure.
A continuous-flow preparation method for an amino alcohol compound using a micro-reaction system. The micro-reaction system includes a feed pump, a micromixer, a microchannel reactor, and a back pressure valve. An aldehyde compound and an amine compound are simultaneously fed to the micro-mixer for mixing to obtain a mixed solution. The mixed solution is directly fed to the micro-channel reactor and undergoes an addition reaction. The reaction mixture is collected, and subjected to concentration, separation and purification to obtain the desired amino alcohol compound.
B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus
C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
25.
COMPOSITIONS AND METHODS OF A CONCOMITANT THERAPY OF ALTERNATING ELECTRIC FIELDS AND NOTCH-1 INHIBITOR
Disclosed are methods of treating a subject in need thereof comprising applying an alternating electric field, to a target site of the subject in need thereof; and administering a a Notch1 inhibitor or Hes5 inhibitor to the subject in need thereof. Disclosed are methods of preventing cancer recurrence in a subject having cancer comprising: applying an alternating electric field to a target site of the subject in need thereof; and administering a Notch1 inhibitor or Hes5 inhibitor to the subject in need thereof. Disclosed are methods of reducing cancer cell growth comprising: applying an alternating electric field to a population of cells comprising one or more cancer cells; and contacting a Notch1 inhibitor or Hes5 inhibitor to the population of cells. Disclosed are methods of sensitizing cancer cells to an alternating electric field comprising: applying an alternating electric field to a population of cells comprising one or more cancer cells; and contacting a Notch1 inhibitor or Hes5 inhibitor to the population of cells.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
An embodiment of the present disclosure provides a leveling agent, which is specifically a polypyridine compound, where the polypyridine compound includes a structural unit shown in Formula (I) or a protonated product of the structural unit shown in Formula (I):
An embodiment of the present disclosure provides a leveling agent, which is specifically a polypyridine compound, where the polypyridine compound includes a structural unit shown in Formula (I) or a protonated product of the structural unit shown in Formula (I):
An embodiment of the present disclosure provides a leveling agent, which is specifically a polypyridine compound, where the polypyridine compound includes a structural unit shown in Formula (I) or a protonated product of the structural unit shown in Formula (I):
In Formula (I), R1 and R2 are independently any one of the following: substituted or unsubstituted alkylene, substituted or unsubstituted arylene, substituted or unsubstituted arylene alkyl, substituted or unsubstituted alkylene aryl, alkylene containing an ether oxygen atom, ester, and/or imide, arylene containing an ether oxygen atom, ester, and/or imide, arylene alkyl containing an ether oxygen atom, ester, and/or imide, and alkylene aryl containing an ether oxygen atom, ester, and/or imide; and R3 is any one of groups such as a single bond, substituted or unsubstituted alkylene, substituted or unsubstituted arylene, substituted or unsubstituted arylene alkyl, and substituted or unsubstituted alkylene aryl.
Provided is an in-vivo in-situ CAR immunotherapy and cancer vaccine combined therapy strategy based on circular RNA, which is a novel tumor immunotherapy that combines the cyclic RNA-based in-vivo in-situ CAR-T/M technology and the circular RNA cancer vaccine technology. This novel tumor immunotherapy enables rapid and efficient generation of CAR-T/M cells in vivo and further produces an enhanced collaborative anti-tumor immunotherapy effect with the synergistic action of the corresponding circular RNA cancer vaccine. In addition, a specific non-complementary region of an I-type intron from tetrahymena is split, and thus in-vitro efficient RNA cyclization can be achieved by means of self-splicing of the I-type intron without requiring homologous arms or additional GTP catalysis.
Disclosed in the present application are compounds having the activity of degrading GSPT1 and an application thereof. The compounds disclosed in the present application have the activity of degrading GSPT1, and can be used for preparing drugs for treating GSPT1 activity-related diseases.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
29.
HYDRAZONE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF
GREATER BAY AREA INSTITUTE OF PRECISION MEDICINE (GUANGZHOU) (China)
FUDAN UNIVERSITY (China)
Inventor
Hou, Steven Xianyu
Shao, Liming
Wang, Yuetong
Li, Ning
Luo, Chenfei
Duan, Shaoliang
Li, Qiaoming
Wang, Xuan
Chen, Ying
Huang, Zhigang
Li, Haisen
Abstract
A hydrazone compound, a pharmaceutical composition thereof, and an application thereof. Specifically, provided is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof. The compound has one or more of the advantages below: good water solubility; relatively low cytotoxicity; good inhibitory activity on Arf1 activation; and possessing and inducing relatively strong anti-tumor immunity.
C07D 209/02 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences (China)
Inventor
Luo, Min
Zhao, Yun
Lu, Zhigang
Abstract
The present disclosure relates to the field of biomedicine, in particular, to a CD300LD inhibitor and use thereof in the preparation of tumor immunotherapy products. In the present disclosure, the CD300LD inhibitor regulates the migration and function of PMN-MDSC cells by modulating S100A8/A9 in its downstream signaling pathway, and plays an important role in the establishment of the tumor microenvironment. The polypeptide isolated by the present disclosure is used as a CD300LD inhibitor, and CD300LD-ECD protein can inhibit CD300LD by competitive binding, thus inhibiting tumor development. When tumor-bearing mice are treated with this peptide, the development of tumors can be significantly inhibited. In addition, CD300LD-ECD has a significant anti-tumor synergistic effect with PD1 antibody.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
SHANGHAI INTEGRATED CIRCUIT MANUFACTURING INNOVATION CENTER CO., LTD. (China)
Inventor
Meng, Jialin
Wang, Tianyu
Chen, Lin
Sun, Qingqing
Zhang, Wei
Abstract
A heterojunction sensing-storage-computing device and a manufacturing method therefor. The heterojunction sensing-storage-computing device comprises: a substrate; a back gate electrode, formed on the substrate; a first gate dielectric layer/second gate dielectric layer/third gate dielectric layer stack, formed on the back gate electrode; one-dimensional nanowires, which are semiconductor materials having a response in a near-infrared band and are formed on the third gate dielectric layer; two-dimensional layered semiconductor materials, which are semiconductor materials having a response in a visible light band, are formed on the third gate dielectric layer, and overlap with the one-dimensional nanowires to form one-dimensional and two-dimensional heterojunctions as channel layers; and source electrodes and drain electrodes, formed on two sides of the corresponding channel layers. Information sensing, storage and computing functions are integrated in a same device unit, thereby improving a photoelectric sensing range and sensitivity of the device, and realizing the storage-computing integrated application with the information sensing capability in the visible-near-infrared band.
H01L 29/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details of semiconductor bodies or of electrodes thereof
H01L 31/113 - Devices sensitive to infrared, visible or ultraviolet radiation characterised by field-effect operation, e.g. junction field-effect photo- transistor being of the conductor-insulator- semiconductor type, e.g. metal- insulator-semiconductor field-effect transistor
H01L 31/0248 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies
H01L 31/18 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof
32.
LEO SATELLITE NETWORK AND FEDERATED LEARNING MODEL CONSTRUCTION METHOD THEREFOR
By combining a federated learning model and a low earth orbit (LEO) satellite network, the present invention provides a general federated learning framework over an LEO satellite network (FedSN) for achieving federated learning. The FedSN is composed of two main components: a sub-structure scheme and pseudo-synchronous model aggregation. The sub-structure scheme comprises sub-structure customization, distribution and aggregation methods, and respectively solves problems such as resource limitations, training imbalance, staleness of intra-group models. According to a pseudo-synchronous model aggregation strategy, the difference between weights of models is brought into a weight function, and a buffer-based aggregation method is developed, so that the staleness of inter-group models is reduced. Extensive experimental results show that a FedSN framework is superior to a state-of-the-art baseline. The present invention shows and improves the potential of deploying a FedSN on an LEO satellite network.
A blowtorch (100) and a plasma deposition apparatus (200). The blowtorch (100) comprises a first pipe fitting (10), a second pipe fitting (20), a third pipe fitting (30), and an auxiliary air inlet pipe (40). The first pipe fitting (10) defines a feeding channel (11), and the first pipe fitting (10) has a feeding end (12) and a discharging end (13) which are oppositely arranged in the length direction of the first pipe fitting. The second pipe fitting (20) is sleeved on the outer side of the first pipe fitting (10), and the second pipe fitting (20) and the first pipe fitting (10) define an auxiliary channel (Q1). The third pipe fitting (30) is sleeved on the outer side of the second pipe fitting (20), and the third pipe fitting (30) and the second pipe fitting (20) define a first cooling channel (Q2). The auxiliary air inlet pipe (40) is connected to the second pipe fitting (20), and the radial distance between the auxiliary air inlet pipe (40) and the second pipe fitting (20) gradually decreases in a direction moving close to the discharging end. The blowtorch structure can improve the deposition efficiency of the blowtorch.
C23C 16/453 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating passing the reaction gases through burners or torches, e.g. atmospheric pressure CVD
Embodiments of the disclosure relate to a method, an apparatus, a device, and a storage medium for information processing. The method proposed herein includes: obtaining a sample question and policy information for solving the sample question; determining, by splitting the policy information, an inference process corresponding to at least one intermediate solution state of the sample question; generating at least one input sample by combining the sample question and the inference process; and adjusting a target model based on the at least one input sample and answer information of at least one sample question.
Provided is a tumor tissue resection-guiding device, comprising a sampling assembly (100) configured for collecting a sample from a tissue surface, a detecting assembly (200) configured for detecting a biomarker in the sample, and a mapping assembly (300) configured for integrating a detection result of the biomarker to an image of the tissue surface.
SHANGHAI INSTITUTE OF MATERIA MEDICA , CHINESE ACADEMY OF SCIENCES (China)
Inventor
Li, Yingxia
Wang, Heyao
He, Yulong
Li, Shunyi
Abstract
Provided are an isoquinolinone compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a prodrug molecule, and a mixture thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as an FABP4/FABP5 dual-targeting inhibitor. Related aryl carboxylic acid compounds can be used for preparing drugs for treating metabolic diseases (such as diabetes, insulin resistance, hyperlipidemia, and atherosclerosis), autoimmune diseases and cancers.
Provided are an isoquinolinone compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a prodrug molecule, and a mixture thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as an FABP4/FABP5 dual-targeting inhibitor. Related aryl carboxylic acid compounds can be used for preparing drugs for treating metabolic diseases (such as diabetes, insulin resistance, hyperlipidemia, and atherosclerosis), autoimmune diseases and cancers.
C07D 217/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
37.
METHOD FOR CONTINUOUS-FLOW AMINATION OF ALKYL CARBOXYLIC ACID COMPOUND
A method for continuous-flow amination for an alkyl carboxylic acid compound is provided, in which an amination reagent and a catalyst are mixed in a first micro-mixer and then preheated in a preheater. The mixture is mixed with a substituted alkyl carboxylic acid solution in a second micro-mixer and reacted in a dynamic flow reactor to produce a mixture including a carboxyl-containing organic amine product. Then, the mixture is subjected to gas-liquid separation, and the liquid phase is collected and filtered to obtain a first filtrate and a first filter residue. The first filter residue is mixed with a base solution under stirring and filtered to obtain a second filtrate and a second filter residue. The second filter residue was dried to yield a high-purity carboxyl-containing organic amine product.
C07C 227/10 - Formation of amino groups in compounds containing carboxyl groups with simultaneously increasing the number of carbon atoms in the carbon skeleton
B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
Provided are a fusion protein and use thereof. Provided is a fusion protein, comprising a trimerization block and an immunogenic block which are connected by a linker, wherein the trimerization block comprises one or more of repeat units set forth in SEQ ID NO. 1; the immunogenic block is an immunogenic protein of a pathogen, for example, being selected from a coronavirus RBD block, an HIV membrane protein or an influenza virus hemagglutinin protein, and immunogenic fragments thereof. Compared with an immunogen monomer, the trimer can generate a higher neutralizing antibody level, does not induce a strong antibody against the trimerization block in a human body, and can promote the immune response of the organism to be focused on the immunogenic block.
A combination of SNP loci for paternity testing, a detection primer pair and an application thereof are provided, belonging to the application research of forensic molecular genetics. The combination of SNP loci includes 520 SNP loci. Based on the combination of SNP loci, all the selected loci in the population conform to Hardy-Weinberg equilibrium (corrected by Bonferroni), and each locus is not linked and is in linkage equilibrium. When selecting loci, references are made to various databases, relevant literature, and genetic markers widely used in forensic science, which allows for obtaining more genetic information and higher forensic efficacy. It is conducive to forensic applications such as individual identification of difficult biological samples and prenatal paternity test of maternal peripheral blood.
Provided is a preparation method for a group I intron-based circular RNA, relating to the technical field of circular RNAs. A specific non-complementary region of a group I intron is split, the method can be generalized to other group I introns, and by means of the principle of ribozyme self-splicing, preparation of a circular RNA is achieved. By optimizing a sequence, when there is no homology arm, efficient cyclization can be achieved without adding GTP for catalysis. In terms of vaccines, a new method for preparing an anti-infectious disease and anti-tumor circular RNA vaccine that produces a high neutralizing antibody and a T cell immune response is provided. In terms of chimeric antigen receptor (CAR) therapy, a method for in vivo engineering of immune cells (including T cells, macrophages, etc.) using a circular RNA-based "off-the-shelf" in vivo CAR is provided, and an anti-tumor immunotherapy drug can be developed and prepared.
A method of preparing an alkyl phosphate compound based on a micro-reaction system. The micro-reaction system includes a feed pump, a first micro-mixer, a second micro-mixer, a first micro-channel reactor, a second micro-channel reactor and a back-pressure device, where the first micro-mixer, the second micro-mixer, the first micro-channel reactor, the second micro-channel reactor and the back-pressure device are sequentially connected. The method includes the following steps. An alkylamine compound and an acid-binding agent are simultaneously fed to a first micro-mixer for mixing and then to the first micro-channel reactor for pre-reaction to obtain a pre-reaction solution. The pre-reaction solution and a phosphate or phosphite are simultaneously fed to the second micro-mixer for mixing to obtain a first reaction mixture. The first reaction mixture is fed to the second micro-channel reactor to carry out a condensation reaction under a back pressure condition and is concentrated to obtain the final product.
A ribonucleic acid (RNA) in-vitro cyclization and rolling circle translation (RCT) method based on a group I intron, and a use. A specific non-complementary region of the group I intron is split to obtain an RNA construct, the preparation of a "scarless" circular RNA is implemented by means of the principle of ribozyme self-splicing, and the method is generalized to other group I introns. By optimizing a split structure, in the absence of homology arms, efficient cyclization can be achieved without the need for additional GTP catalysis. Additionally, the components of the RNA construct are optimized, thereby further improving the cyclization efficiency. An RCT technology platform based on a CITE sequence is established, thereby greatly improving the expression level of a protein or polypeptide. It has been verified that the cyclization and RCT method shows potential in vaccine and CAR treatment, and is expected to be used in the clinical treatment of various diseases.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C12N 15/65 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression using markers
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
A61K 39/00 - Medicinal preparations containing antigens or antibodies
43.
PROTEIN DEGRADERS DEVELOPED ON BASIS OF BCL-2 FAMILY PROTEIN LIGAND COMPOUNDS AND USE THEREOF
The present disclosure provides protein degraders developed based on BCL-2 family protein lig and compounds, including compounds of Formula (I) or their salts, enantiomers, stereoisomers, solvates, prodrugs, or polymorphs, and their applications for treating diseases.
The present disclosure provides protein degraders developed based on BCL-2 family protein lig and compounds, including compounds of Formula (I) or their salts, enantiomers, stereoisomers, solvates, prodrugs, or polymorphs, and their applications for treating diseases.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/02 - Antineoplastic agents specific for leukemia
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
44.
WHOLE-PROCESS TARGETING POLYPEPTIDE, PHARMACEUTICAL COMPLEX THEREOF, DRUG DELIVERY SYSTEM AND USE THEREOF
Provided are a whole-process targeting polypeptide, a pharmaceutical complex thereof, a drug delivery system and the use thereof. The whole-process targeting polypeptide comprises pHA and a VAP which are covalently linked by means of a bridging structure; and the VAP is LVAP, a retro polypeptide of LVAP, DVAP or SVAP, the amino acid sequence of LVAP being as shown as SEQ ID NO: 1, SVAP being a D-configuration polypeptide of LVAP, DVAP being a D-configuration polypeptide of a retro polypeptide of LVAP, and the bridging structure being amino-monoethylene glycol-carboxylic acid, or a derivative thereof. The whole-process targeting polypeptide can cross the blood-brain barrier and target new blood vessels of tumors, can cross the blood-tumor barrier and target tumor vasculogenic mimicry-derived channels, tumor cells and stem cells thereof, and has better tumor cell affinity, anti-tumor treatment effect and in-vivo safety effect. In addition, when being combined with chemotherapeutic drugs, the pharmaceutical complex or the drug delivery system has a synergistic effect, thereby remarkably improving the anti-tumor pharmaceutical effect.
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
SHANGHAI CHARTWELL MEDICAL SCIENCE & TECHNOLOGY CO., LTD. (China)
Inventor
Ji, Bin
Kai, Mototora
Abstract
The present invention provides a compound represented by general formula (I) or a pharmaceutically acceptable salt, precursor, or solvate thereof, and a use thereof in the preparation of a drug for diagnosing diabetic nephropathy. General formula (I), wherein X is selected from carbon or nitrogen; R1is selected from hydrogen or alkyl; R2is one or more substituents on the benzene ring or the pyridine ring, and R2is independently selected from one or more of hydrogen, halogen, hydroxyl, cyano, nitro, amino, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkoxy, C1-C6 alkylamino, C3-C6 cycloalkylamino, halo C1-C6 alkyl, halo C3-C6 cycloalkyl, halo C1-C6 alkoxy, halo C3-C6 cycloalkoxy, halo C1-C6 alkylamino, halo C3-C6 cycloalkylamino, C6-C8 aryl, or C5-C8 heteroaryl, and in these substituents represented by R2, at least one atom or the entire substituent is replaced by a radionuclide. The drug and method for diagnosing diabetic nephropathy according to the present invention relate to non-invasive diagnosis technology and have the advantages of causing less pain to a subject and having less contraindications.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
46.
FUSION PROTEIN FOR INACTIVATING CORONAVIRUS AND USE THEREOF
Provided in the present invention are a fusion protein for inactivating a coronavirus and the use thereof in the treatment of a coronavirus infection. The fusion protein comprises an ACE2 peptidase domain and a coronavirus polypeptide therapeutic agent targeting an HR1 domain, which are directly linked or are linked via a linker. The ACE2 peptidase domain comprises an amino acid sequence as shown in SEQ ID NO: 1.
Polyphenol compounds, a preparation method therefor and the use thereof. Specifically provided are polyphenol compounds shown as formula X, stereoisomers thereof, or pharmaceutically acceptable salts thereof. The compounds have a remarkable protection effect on an OGD/R-induced in-vitro cerebral ischemia model, can significantly inhibit the inflammation and apoptosis reaction of neurons, and can reduce the volume of cerebral infarction in mice suffering from cerebral ischemia. Additionally, the compounds have reduced polarity, thus improving the oral bioavailability and the proportion of passing through the blood-brain barrier.
C07D 311/62 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 25/00 - Drugs for disorders of the nervous system
A61P 9/00 - Drugs for disorders of the cardiovascular system
48.
SOLVENT-FREE SYNTHESIS METHOD FOR ORDERED MESOPOROUS CARBON MATERIAL, AND SILICON-CARBON NEGATIVE ELECTRODE MATERIAL DERIVED THEREFROM AND USE THEREOF
The present invention relates to the technical field of lithium-ion battery materials, and particularly relates to a solvent-free synthesis method for an ordered mesoporous carbon material, a silicon-carbon negative electrode material derived therefrom and the use thereof. In the present invention, a surfactant, a carbon precursor and a catalyst are ground and uniformly mixed to perform a reaction, and are then carbonized under atmosphere protection to obtain an ordered mesoporous carbon material; and furthermore, a silane is introduced into a container, in which the ordered mesoporous carbon material is placed, for reaction, so as to obtain a silicon-carbon negative electrode material. The ordered mesoporous carbon material in the present invention has a uniform pore diameter and good pore connectivity, can ensure uniform deposition of monatomic silicon, and effectively improves the stability and consistency of the finally obtained silicon-carbon material.
An exposure device for exposing microorganisms to gaseous pollutants and a corresponding in-situ multi-toxicity endpoint detection system are provided. The detection system based on the exposure device disclosed in the present application may perform controlled accumulation of pollutants in air, and implements in-situ, comprehensive, quick, and low-cost assessment of toxicity effects of pollutants in air of a target site. The exposure device and the detection system disclosed in the present application can effectively avoid toxicity distortion caused by complex collection and transfer process, complex chemical reactions in a liquid elution process in conventional toxicity detection methods for gaseous pollutants.
A rapidly constructed three-dimensional model of a microbial film exposed at an air-liquid interface and a preparation method thereof, as well as a hydrogel bead containing microorganisms immobilized at an air-liquid interface in an exposed state and a preparation method thereof. The model includes a hydrogel material containing gradually releasable nutrients, as a core scaffold; a hydrogel film attached to a surface of core and wrapping microorganisms, as a biofilm-like film; and an antimicrobial polyelectrolyte layer between the biofilm-like film structure and the core structure which allows substances in the core to be released into the biofilm-like film structure while preventing the microorganisms on the film from migrating to the core material, ensuring uniform distribution of the microorganisms on the surface of the core and maintaining the microorganisms continuously exposed at the air-liquid interface.
The invention provides a multi-dimensional broad-spectrum clinical in-situ testing equipment designed to evaluate the material properties of plantar soft tissue. The equipment comprises the following features: 1. A testing table with a designated area corresponding to the sole of the foot; 2. A vertical reciprocating stress-strain testing unit mounted on the testing table, for applying vertical tensile and compressive stresses to the plantar and measuring the stress-strain responses; 3. A shear stress-strain testing unit, mounted on the testing table, for applying shear stresses to the plantar and measuring the stress-strain responses; 4. A torque stress-strain detection unit, positioned on the testing stage, for applying torque to the plantar and measuring the stress-strain responses; 5. A lifting mechanism that facilitates the vertical movement of the three testing units. In conclusion, the device is capable of multi-dimensional detection of the mechanical properties of plantar and features a compact structure and easy portability.
A polymer material, specifically a sugar backbone polymer and a synthesis method. A new type of sugar backbone polymer is prepared using a condensation and polymerization method. An addition reaction of alcohol-olefin is introduced into the synthesis of the sugar backbone polymer, to form a new functional primary sugar chain alternating polymer having alternating sugar and aliphatic units. It overcomes shortcomings of existing artificial chemical synthesis methods such as difficulty in controlling the stereoselectivity of the product, low molecular weight, cumbersome monomer preparation and few types. The molecular weight of the prepared polymer can reach 71,067 g/mol, and monomer preparation is simple.
This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a polymer-drug nanoaggregate having a polymer and at least one bioactive agent that can comprise STING polypeptide, a nucleic acid encoding said STING polypeptide, a STING inhibitor, a STING activator, a STING agonist, a STING antagonist, a STING modulating molecule, or a combination thereof. The pharmaceutical composition can be a vaccine or an adjuvant for a vaccine. This disclosure is also directed to a method for treating or preventing a disease using the pharmaceutical composition. The disease can include infectious diseases caused by viruses or other pathogens, for example, influenza, rabies, or respiratory illnesses such as severe acute respiratory syndrome (SARS) caused by coronaviruses, such as MERS-CoV, SARS-CoV, and Coronavirus Disease 2019 (COVID-19) caused by the virus SARS-CoV-2 and its variants.
An anti-SARS-CoV-2 virus protein or mRNA vaccine, a preparation method therefor, and a use thereof. The protein has one or more amino acid residues added, deleted, or replaced in the amino acid sequence as shown in SEQ ID NO: 18. The nucleic acid encodes an S protein mutant. Preclinical animal test data shows that the mRNA vaccine has a good protective effect for the current variants of concern (VOC) of the SARS-CoV-2 virus and has broad clinical application prospects.
The present application relates to the technical field of biological testing, and in particular, to a biological sample testing method, system, apparatus and kit, and a use. The biological sample testing method comprises the following steps: taking a test probe and dissolving same in a solvent to prepare a test probe solution, and connecting the test probe solution to a test electrode; taking a blank solvent and connecting the blank solvent to a reference electrode; inputting power supply signals to the test electrode and the reference electrode, using a measurement module to test and record respective charging and discharging frequencies, setting a frequency difference to 0 by means of the measurement module, and disconnecting the test probe solution from the test electrode when the setting is completed; taking a biological sample to be tested, adding a test probe for specific binding, to prepare a test solution, and connecting the test probe solution to the test electrode; and inputting power supply signals to the test electrode and the reference electrode, using the measurement module to test and record respective charging and discharging frequencies, calculating a difference, and distinguishing different biological samples on the basis of the differences obtained by calculation. The method is accurate, efficient, and fast, so that the test time is greatly shortened and the test cost is saved.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
C12Q 1/6816 - Hybridisation assays characterised by the detection means
A broad-spectrum influenza A vaccine immunogen composition and the use thereof. Provided is a nucleic acid molecule encoding an immunogenic peptide, the immunogenic peptide comprising: tandem M2e peptide fragments, an HA2 peptide fragment derived from influenza virus H7N9 subtype; a multimerized motif peptide fragment, and optionally, one or more linker peptide fragments independently located between the peptide fragments, the nucleic acid molecule comprising encoding nucleic acids of the peptide fragments. The broad-spectrum influenza A vaccine can induce organisms to generate antigen-specific immune responses, and can generate a high-titer antibody just in 14 days after the last vaccination, which can completely prevent attacks from various influenza A virus subtypes.
The present invention discloses a method for preparing a highly crystalline two-dimensional MWW zeolite, comprising following steps S1-S3. Step S1 includes adding powder of two-dimensional materials into a reaction vessel, dripping an organic structure-directing agent and mixing uniformly to obtain a mixture, performing an ultrasonic treatment and centrifugation on the mixture, and collecting upper clear liquid to obtain a thin-layered dispersed solution of the two-dimensional materials after liquid phase exfoliation. Step S2 includes combing the thin-layered dispersed solution, deionized water/organic structure-directing agent, alkali metal source, and aluminum source to form a solution, slowly adding a silicon source to the solution, stirring the mixture to dissolve, and aging the mixture to obtain a sol-gel. Step S3 includes configuring the sol-gel to undergo hydrothermal crystallization to produce a reaction product, and washing, centrifuging, and drying the reaction product to obtain a highly crystalline two-dimensional MWW zeolite. In this invention, hexagonal boron nitride or molybdenum sulfide is used as a template for the epitaxial growth of two-dimensional zeolite, eliminating the need for additional organic templating agents beyond hexamethyleneimine or piperidine. This synthesis yields a two-dimensional MWW zeolite with excellent crystallinity and a high aspect ratio.
C01B 39/04 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereofDirect preparation thereofPreparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactantsAfter-treatment thereof using at least one organic template directing agent, e.g. an ionic quaternary ammonium compound or an aminated compound
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
B82Y 40/00 - Manufacture or treatment of nanostructures
B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
B01J 29/70 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of types characterised by their specific structure not provided for in groups
The present invention relates to the technical field of wireless communications, and in particular to a compact transformer power combining network. The transformer power combining network of the present invention is composed of two primary inductors, two secondary inductors, and two resonant inductors. The primary inductors and the secondary inductors correspond to coupling coils of a transformer, and are used for realizing the functions of impedance matching, power combining, and differential-to-single-ended conversion. The resonant inductors are connected between the differential primary inductors, and are used for realizing the functions of eliminating the parasitic capacitance power loss and enhancing the electromagnetic coupling. The structure of the compact transformer power combining network is in a symmetrical form: two transformer cores are symmetrically arranged left and right. The transformer power combining network can enhance the electromagnetic induction, decreases the area required by the inductors, and reduces the circuit costs, i.e., having the advantages of low loss and low costs, and is applicable to communication applications with high carrier frequencies such as WLAN and 5G.
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
FUDAN UNIVERSITY (China)
Inventor
De La Fuente-Nunez, César
Der Torossian Torres, Marcelo
Pedro Fragao Bento Coelho, Luis
Dias Santos Júnior, Célio
Abstract
Novel antibiotics are needed to combat the antibiotic-resistance crisis. Presented herein are machine learning-based approaches for predicting antimicrobial peptides (AMPs) within the global microbiome and leverage a vast dataset that can include metagenomes and prokaryotic genomes from environmental and host-associated habitats to create a comprehensive catalog comprising distinct, non-redundant peptides, the majority of which are novel. This platform provides insights into the evolutionary origins of peptides, including by duplication or gene truncation of longer sequences. To validate predictions, 100 AMPs were synthesized and tested against clinically relevant drug-resistant pathogens and human gut commensals, both in vitro and in vivo. Many of the synthesized peptides were active, with a large number of them targeting pathogens. The presently described computational approach can identify millions of prokaryotic AMP sequences, opening new avenues for antibiotic discovery.
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16B 25/00 - ICT specially adapted for hybridisationICT specially adapted for gene or protein expression
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics
60.
Semi-online analytical apparatus for measuring atmospheric trace nitrogen-containing organic components
The present invention relates to a visible-light-mediated one-step method for preparing phenol and cyclohexanone from cyclohexylbenzene (CHB). The method specifically comprises: under the irradiation of visible light, and with a hydrogen bromide solution as a catalyst and oxygen as an oxidizing agent, directly oxidizing cyclohexylbenzene in an organic solvent to break a carbon-carbon bond, so as to generate phenol and cyclohexanone. The method avoids such a process in a cyclohexylbenzene method in the prior art that cyclohexylbenzene needs to be first oxidized to obtain cyclohexylbenzene-1-hydroperoxide (1-CHBHP), then the mixture of the oxidation reaction products is treated, and then a cyclohexylbenzene peroxide is decomposed in an acidic condition to obtain phenol and cyclohexanone, and also avoids potential risks caused by the accumulation of peroxides. In addition, the method further has a great number of advantages of the operation being simple, reagents being easily available, reaction conditions being mild, easy control being achievable, the reaction being able to be scaled-up, a good selectivity being obtained, etc.
C07C 37/60 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by oxidation reactions introducing directly a hydroxy group on a CH-group belonging to a six-membered aromatic ring with the aid of other oxidants than molecular oxygen or their mixtures with molecular oxygen
C07C 45/33 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by oxidation with molecular oxygen of CHx-moieties
62.
SMALL MOLECULE TRACER FOR IMAGING ALPHA-SYNUCLEIN AGGREGATES
The invention discloses a type of compound that can specifically bind to α-synuclein aggregates represented by Formula I, a radio-labelled compound thereof, a preparation method, and its use. The compound can be used as a tracer for optical imaging of α-synuclein aggregates in biological samples or in vivo (such as the brain). After radio-labelled, the compound of the invention can be used as a radio imaging tracer for PET, SPECT, and other imaging techniques to realize the detection of α-synuclein lesions by non-invasive visualization in vivo (such as the brain).
The invention discloses a type of compound that can specifically bind to α-synuclein aggregates represented by Formula I, a radio-labelled compound thereof, a preparation method, and its use. The compound can be used as a tracer for optical imaging of α-synuclein aggregates in biological samples or in vivo (such as the brain). After radio-labelled, the compound of the invention can be used as a radio imaging tracer for PET, SPECT, and other imaging techniques to realize the detection of α-synuclein lesions by non-invasive visualization in vivo (such as the brain).
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
63.
METHOD AND APPARATUS FOR REWRITING NARRATIVE TEXT, DEVICE, AND MEDIUM
According to embodiments of the present disclosure, a method and apparatus for rewriting a narrative text, a device, and a medium are provided. The method includes determining a change to a sentence in a narrative text. An initial context of the sentence before the change is different from a target context of a changed sentence. The method further includes performing, based on inconsistency between a text part after the sentence in the narrative text and the target context, at least one edit operation on the text part to generate at least one edited version of the text part. The method further includes replacing the text part with an edited version in the at least one edited version to obtain a rewritten narrative text. In this way, the narrative text can be rewritten with a small number of edits while ensuring contextual coherence.
A series of 2-(5-substituted-indolone-3-yl-hydrozono)-3-substituted-arylidene-1,3-thiazolidinone derivatives represented by
A series of 2-(5-substituted-indolone-3-yl-hydrozono)-3-substituted-arylidene-1,3-thiazolidinone derivatives represented by
A series of 2-(5-substituted-indolone-3-yl-hydrozono)-3-substituted-arylidene-1,3-thiazolidinone derivatives represented by
where R1 is Cl, F, Br or CH3, and R2 is 4-F, 3-Cl, 3-CF3 or 4-C(CH3)3. A pharmaceutical composition including such 2-(5-substituted-indolone-3-yl-hydrozono)-3-substituted-arylidene-1,3-thiazolidinone derivative, or a pharmaceutically-acceptable salt thereof is provided. A preparation method of such derivative and an application of such derivative as a lead compound in the preparation of PARP14 inhibitors are further provided.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
65.
SUBSTANCE COMPONENT DETECTION APPARATUS AND METHOD
A substance component detection apparatus and a method are provided to reduce absorption of an infrared signal by a window medium, thereby obtaining abundant fingerprint region signals. The apparatus includes: a sample pool, an infrared optical window, an infrared light source, and a detector. The infrared optical window has a first surface that faces an inner side of the sample pool and that is configured to be in contact with a to-be-detected substance, and a second surface exposed on an outer side of the sample pool. A protruding portion is formed between two adjacent grooves on the second surface, and any protruding portion has an incident surface and an emergent surface. An infrared signal emitted by the infrared light source is irradiated on the incident surface. The detector determines a component of the to-be-detected substance and/or content of the component.
G01N 21/3577 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing liquids, e.g. polluted water
66.
FIN FIELD-EFFECT TRANSISTOR DEVICE WITH HYBRID CONDUCTION MECHANISM
SHANGHAI INTEGRATED CIRCUIT MANUFACTURING INNOVATION CENTER CO., LTD. (China)
Inventor
Wu, Chunlei
Xu, Yumin
Shen, Boqian
Zhao, Fei
Yang, Zichen
Zhang, Wei
Xu, Min
Abstract
A fin field-effect transistor device with hybrid conduction mechanism, including a fin field-effect transistor, a second source region, and a second drain region; the fin field-effect transistor includes a substrate, a fin channel region, a first source region, and a first drain region; the height of the second source region is not lower than the height of the substrate between the first source region and the first drain region; the first source region, the first drain region and the second drain region are doped with first ions; the second source region is formed between the substrate and the first source region, the second drain region is formed between the substrate and the first drain region, the second source region is doped with second ions. This scheme can realize hybrid conduction of fin channel diffusion drift current and bottom channel band-to-band tunneling current, thus obtaining better ultra-steep switching characteristics.
H01L 29/08 - Semiconductor bodies characterised by the shapes, relative sizes, or dispositions of the semiconductor regions with semiconductor regions connected to an electrode carrying current to be rectified, amplified, or switched and such electrode being part of a semiconductor device which comprises three or more electrodes
H01L 29/10 - Semiconductor bodies characterised by the shapes, relative sizes, or dispositions of the semiconductor regions with semiconductor regions connected to an electrode not carrying current to be rectified, amplified, or switched and such electrode being part of a semiconductor device which comprises three or more electrodes
H01L 29/78 - Field-effect transistors with field effect produced by an insulated gate
67.
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USES THEREOF
A nucleic acid, a pharmaceutical composition and conjugate containing the nucleic acid, and uses thereof. In particular, the present invention relates to an siRNA, having a sense strand and an antisense strand that are complementary to each other. Nucleotides in the siRNA are each independently a modified or unmodified nucleotide. The sense strand of the siRNA contains a sequence SEQ ID NO: 1, 21 or 23 or a sequence that differs by no more than four nucleotides therefrom, and the antisense strand of the siRNA contains a sequence SEQ ID NO: 2, 22 or 24 or a sequence that differs by no more than four nucleotides therefrom. The present invention further provides a nucleic acid group comprising the nucleic acid as a first siRNA, and a second siRNA which contains a sense strand containing a sequence as shown in SEQ ID NO: 5, 7 or 43 and an antisense strand containing a sequence as shown in SEQ ID NO: 6, 8 or 44, a pharmaceutical composition and conjugate containing the nucleic acid or the nucleic acid group, and uses thereof.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
The present invention provides an imidazolium salt macrocyclic compound, and a preparation method therefor and a use thereof. Specifically disclosed are a macrocyclic compound as shown in formula (I) or a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and a use of a composition which is formed of same with a pharmaceutically acceptable carrier and capable of producing neuromuscular junction block in the preparation of muscle relaxants.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61P 21/02 - Muscle relaxants, e.g. for tetanus or cramps
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
69.
ALKOXY THIOPHENE ACYL ARYLAMINE COMPOUNDS AND USE THEREOF
The present invention provides alkoxy thiophene acyl arylamine compounds and a use thereof, comprising alkoxy thiophene acyl arylamine compounds having a structure as shown in formula (1), or pharmaceutically acceptable salts thereof. The alkoxy thiophene acyl arylamine compounds provided by the present invention are a class of novel sphingomyelin synthase inhibitors, which have significant inhibitory activity against SMS2, ideal physical and chemical properties such as stability and water solubility, and low potential for toxic side effects, and can be further made into a drug for preventing or treating diseases related to abnormal sphingomyelin levels.
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A biosynthesis method for a broad-spectrum antiviral polypeptide. The present invention specifically relates to a biosynthesis method for a polypeptide HCoV-EK1 capable of inhibiting human coronavirus infections in a broad-spectrum manner. The specific process comprises: construction of an Escherichia coli genetically engineered bacterium, fermentation culture of the Escherichia coli genetically engineered bacterium, and purification of recombinant polypeptide HCoV-EK1.
GREATER BAY AREA INSTITUTE OF PRECISION MEDICINE (GUANGZHOU) (China)
FUDAN UNIVERSITY (China)
Inventor
Chen, Guosong
Zhao, Liman
Yang, Jing
Zeng, Ya
Abstract
The present invention relates to the field of biomedicine, and provides a glycopeptide molecule. According to the glycopeptide molecule, an oligosaccharide fragment is bound to an oligopeptide fragment to construct a glycopeptide molecule or glycopeptide assembly having a function of promoting osteogenesis. The glycopeptide molecule is safer, has fewer side effects, and can effectively prevent and treat osteoporosis.
The present invention relates to a regeneration processing method for a degradable high polymer material, and a use, comprising the following steps: in a system in which an organic non-metallic catalyst and an aqueous solvent are present, performing degradation processing on a degradable high polymer material, to obtain a degradation product, the degradable high polymer material comprising one or more of a polyester material and a polycarbonate material, and the organic non-metallic catalyst being one or more selected from among a diphenyl phosphate, a binaphthyl phosphate and an organic base.
Provided in the present invention is a center-tapped on-chip transformer having low alternating-current impedance. The center-tapped on-chip transformer comprises a center tap, a primary coil and a secondary coil, wherein the secondary coil and the primary coil are spaced apart from each other by means of a dielectric layer; and the center tap is electrically connected to the primary coil, and comprises a power line, a capacitor cell and a ground wire, the power line being electrically connected to one end of the capacitor cell, and the ground wire being electrically connected to the other end of the capacitor cell. The center-tapped on-chip transformer having low alternating-current impedance provided in the present invention reduces impedance at a center tap, and reduces parasitic inductance generated by a power line, thereby improving the performance of the transformer.
H01F 29/02 - Variable transformers or inductances not covered by group with tappings on coil or windingVariable transformers or inductances not covered by group with provision for rearrangement or interconnection of windings
H01F 27/34 - Special means for preventing or reducing unwanted electric or magnetic effects, e.g. no-load losses, reactive currents, harmonics, oscillations, leakage fields
74.
GATE-ALL-AROUND TRANSISTOR WITH HYBRID CONDUCTION MECHANISM AND MANUFACTURING METHOD THEREOF
SHANGHAI INTEGRATED CIRCUIT MANUFACTURING INNOVATION CENTER CO., LTD. (China)
Inventor
Wu, Chunlei
Xu, Yumin
Shen, Boqian
Zhao, Fei
Yang, Zichen
Zhang, Wei
Xu, Min
Abstract
A gate-all-around transistor with hybrid conduction mechanism, including a GAA MOSFET, a second source region, and a second drain region. The GAA MOSFET includes a substrate, a first source region, and a first drain region. The first source region, the first drain region and the second drain region are doped with first ions, the second source region is doped with second ions. The second source region is formed between the substrate and the first source region, the second drain region is formed between the substrate and the first drain region. The height of the second source region and the second drain region are not less than the height of the substrate between the first source region and the first drain region. It can realize the hybrid conduction of the gate channel diffusion drift current and the bottom channel band tunneling current to obtain better ultra-steep switching characteristics.
H01L 27/06 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including integrated passive circuit elements with at least one potential-jump barrier or surface barrier the substrate being a semiconductor body including a plurality of individual components in a non-repetitive configuration
H01L 29/06 - Semiconductor bodies characterised by the shapes, relative sizes, or dispositions of the semiconductor regions
H01L 29/16 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only elements of Group IV of the Periodic System in uncombined form
H01L 29/20 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only AIIIBV compounds
H01L 29/22 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only AIIBVI compounds
H01L 29/423 - Electrodes characterised by their shape, relative sizes or dispositions not carrying the current to be rectified, amplified or switched
The invention relates to precision measurement technology, specifically a high-sensitivity three-dimensional topography recovery method using dual-channel differentiation. Enhancing a traditional microscopic imaging system, a beam splitter is added between the objective lens and tube lens. This creates an additional light path equipped with a tube lens and camera identical to the original but with a slightly different distance to the camera. During axial scanning of the object, focusing evaluation function curves for each pixel are calculated from images captured by both cameras. The curves from the two cameras show more significant changes near the optimal focusing depth, improving system sensitivity. This method enhances sensitivity by hardware-fixed differentiation of the focusing evaluation function, while maintaining high scanning efficiency and flexible configuration.
The present invention relates to an antibody against a hepatitis B surface antigen (HBsAg) and an antigen-binding fragment thereof, and methods for preparing and using the antibody and the antigen-binding fragment thereof. The present invention further relates to bispecific antibodies that specifically bind to different epitopes on HBsAg. The antibodies are derived from persons inoculated with hepatitis B vaccines and persons having recovered from hepatitis B infections, show superior effects in recognizing different hepatitis B surface antigens, and have greater advantages in neutralizing hepatitis B virus mutants and reducing hepatitis B mutant antigens.
A sustained-release gel with insoluble salt as pH adjuster, and its preparation method and application are disclosed. The sustained-release gel is obtained by dissolving polymer in an aqueous solvent, followed by blending and compounding the alkaline inclusion and the insoluble salt crystalline powder. The insoluble salt is at solid state and thus has thus a large amount as the reservoir of the pH adjuster. The preparation is injectable, can be converted into gel state after being injected into organism, and realizes the sustained release of the inclusion at the injection site. The presence of the insoluble salt reduces the solubility of the inclusion in the gel by releasing the free salt sustainably and thus adjusting the pH inside the gel in a sustained manner. The burst release of the inclusion out of the gel is significantly alleviated.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
78.
STABLE RNA MOLECULE PREPARED IN VITRO AND USE THEREOF IN PREPARATION OF IN-VIVO IN-SITU CAR TREATMENT PRODUCT
A stable RNA molecule prepared in vitro and a use thereof in preparation of an in-vivo in-situ CAR treatment product, wherein mRNA is redesigned, and protective RNA secondary structures are added to two ends of the mRNA to protect the mRNA from being cut by an RNA exonuclease, thereby improving the stability of RNA; moreover, IRES is used for replacing a 5'-terminal m7G cap structure to recruit ribosomes to start protein translation, so that the mRNA retains a translation function, the stability of the mRNA is improved, and there is no need to add caps and tails to the two ends of the mRNA, thereby greatly reducing the preparation cost of the mRNA, and improving the in-vitro production efficiency of the mRNA. Besides, on this basis, a polycistronic RNA platform is constructed, IRESs are used for expressing a plurality of protein sequences, respectively, making up for the deficiency that monocistronic RNA technology cannot be used to simultaneously express a plurality of functional proteins.
Relating to the technical field of biological medicine, particularly the use of a kinase domain M7CK of TRPM7 in the preparation of a drug for treating Alzheimer's disease. The over-expression of M7CK can relieve cognitive impairment of a mouse model with AD by increasing an MMP14 phosphorylation level, improving learning and memory ability, increasing synaptic density and density of a presynaptic vesicle protein synaptophysin and a postsynaptic density protein PSD-95, promoting degradation of Aβ in soluble and insoluble components, and reducing accumulation of Aβ amyloid plaques. Therefore, the kinase domain of TRPM7 provided has a great application prospect in gene therapy of a patient with Alzheimer's disease
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
81.
GATE ALL AROUND (GAA) TRANSISTOR DEVICE HAVING U-SHAPED GATE AT BOTTOM AND MANUFACTURING METHOD, AND APPARATUS AND MANUFACTURING METHOD
SHANGHAI INTEGRATED CIRCUIT MANUFACTURING INNOVATION CENTER CO., LTD. (China)
Inventor
Wu, Chunlei
Xu, Yumin
Shen, Boqian
Zhao, Fei
Yang, Zichen
Zhang, Wei
Abstract
A Gate All Around (GAA) transistor device having a U-shaped gate at the bottom, comprising: a substrate (101), a first source region (109), a first drain region (110), a first control gate, and a first channel layer, wherein first ions are doped in the first source region (109) and the first drain region (110), the first channel layer is the channel layer most proximate to the substrate, and the first control gate is the control gate most proximate to the substrate; a second source region (107) formed between the substrate (101) and the first source region (109), and a second drain region (108) formed between the substrate (101) and the first drain region (110), wherein first ions are doped in the second drain region (108), second ions are doped in the second source region (107), and the type of the first ions is different from that of the second ions; the thickness of the first control gate in a second direction is greater than that of other control gates in the second direction; in the second direction, first surfaces of the second source region (107) and the second drain region (108) are not higher than the bottom surface of the first channel layer, and second surfaces are not lower than the surface of the substrate (101) between the second source region (107) and the second drain region (108). The technical solution solves the problem of direct tunneling of a source and a drain in the GAA transistor device while preventing leakage of a bottom parasitic channel.
SHANGHAI INTEGRATED CIRCUIT MANUFACTURING INNOVATION CENTER CO., LTD. (China)
Inventor
Wu, Chunlei
Xu, Yumin
Shen, Boqian
Zhao, Fei
Yang, Zichen
Zhang, Wei
Abstract
Provided in the present invention is a gate-all-around transistor based on a hybrid conduction mechanism, the gate-all-around transistor comprising: a gate-all-around MOSFET device, which comprises a substrate, a first source region, a first drain region, a first gate dielectric layer, and a gate-all-around channel control gate, wherein the first source region and the first drain region are doped with first ions; a second source region, which is formed between the substrate and the first source region, and a second drain region, which is formed between the substrate and the first drain region, wherein the height of the second source region and the height of the second drain region are not less than the height of the substrate between the first source region and the first drain region, the second drain region is doped with the first ions, and the second source region is doped with second ions; and a bottom control gate, wherein the bottom control gate covers the surface of the gate dielectric layer on the substrate, the gate-all-around channel control gate covers the surface of the bottom control gate, and the difference between a work function of the bottom control gate and that of the gate-all-around channel control gate is greater than 0.5 eV. This technical solution solves the problem of it not being possible to highlight the characteristic of an ultra-steep subthreshold swing being less than 60 mV/dec in a bottom subthreshold region.
H01L 29/78 - Field-effect transistors with field effect produced by an insulated gate
H01L 21/336 - Field-effect transistors with an insulated gate
H01L 29/08 - Semiconductor bodies characterised by the shapes, relative sizes, or dispositions of the semiconductor regions with semiconductor regions connected to an electrode carrying current to be rectified, amplified, or switched and such electrode being part of a semiconductor device which comprises three or more electrodes
83.
USE OF RECOMBINANT EXPRESSED PROTEIN IN PREVENTION AND/OR TREATMENT OF RESPIRATORY DISEASE
A use of a recombinant expressed protein in prevention and/or treatment of a respiratory disease. Provided is a use of two recombinant expressed proteins in preparation of a drug for prevention and/or treatment of a respiratory disease. The respiratory disease is caused by influenza A virus infection or co-infection of influenza A virus and novel coronavirus. GRFT has an amino acid sequence shown in SEQ ID NO: 1, and GL25E has an amino acid sequence shown in SEQ ID NO: 2. The recombinant protein GRFT and fusion protein GL25E can effectively inhibit the influenza A virus infection, wherein GL25E is formed by coupling an EK1 polypeptide on the basis of GRFT, the recombinant protein GRFT and fusion protein GL25E have good inhibitory activity against influenza A virus, also have good inhibitory activity against the co-infection of influenza virus and novel coronavirus, and can be used in preparation of drugs for prevention and/or treatment of respiratory diseases caused by influenza virus and the co-infection of influenza virus and coronavirus.
The present application provides a method for preparing a deuterated chemical by means of a deuteration reaction of a carbon-hydrogen bond with a deuterium gas under the catalysis of an alkali, wherein in the presence of a catalyst, a deuterium gas is added into a compound containing a carbon-hydrogen bond for a deuteration reaction so as to generate a deuterated compound. A deuterium gas is used as a deuterium source, such that multiple water separation operations, tedious steps and the wasting of energy caused by usage of a large amount of deuterium oxide as a deuterium source are avoided. Moreover, a cheap and easily available alkali metal compound is used for replacing an expensive transition metal catalyst and a complex-structure ligand as a catalyst for a deuteration reaction, and the alkali metal compound has the advantages of a low cost, a good compatibility with functional groups of a substrate and a high deuteration rate. The present application provides a new, low-cost, green and efficient deuteration method, which has a high application value.
Disclosed in the present invention are a split-gate silicon carbide device with a buried field-limiting ring and a method for preparing same. Said device sequentially comprises, from bottom to top, a drain electrode, a drift region, and a P-well region, and further comprises a U-shaped groove that penetrates through the P-well region; a buried P-type field-limiting ring, formed on the periphery of the bottom of the groove; a P+region and an N+ region, connected to each other and formed on the P-well region on both sides of the groove; a gate electrode, formed in the groove and comprising a transistor gate electrode located on the outer side and a field-limiting ring contact bolt located in the middle area, the transistor gate electrode being wrapped by an oxide layer, the top of the field-limiting ring contact bolt being connected to a source electrode, and the bottom of the field-limiting ring contact bolt being connected to the buried P-type field-limiting ring; and the source electrode, covering the surface of the device, wherein the P-type field-limiting ring is connected to the source electrode by means of the field-limiting ring contact bolt to realize a potential equal to the source electrode, thereby reducing the electric field in the oxide layer of the gate electrode on both sides of the groove, and enabling a depletion region of the device in a reverse bias state to be limited outside channel regions on both sides.
Use of an anti-inflammatory drug in resisting CRS caused by CART therapy. Specifically, in CART therapy, the use of an anti-inflammatory drug can effectively reduce various side effects of immunotherapy such as CART therapy, TCRT therapy, and antibody therapy, such as weight loss, fever and other CRS-related symptoms.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/265 - Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A focused ultrasound treatment system has: a focused ultrasound unit configured to emit focused ultrasound waves to a focal region to perform treatment; an ultrasound imaging unit configured to, after treatment emit imaging ultrasonic waves to an imaging region and receive corresponding echoes, and image a corresponding vascular blood flow image on the basis of the echo; a region planning and parameter adjustment unit configured to re-delineate a focal region on the basis of the vascular blood flow image and to re-adjust a treatment parameter of the focused ultrasound unit so as to be used to next treat the re-delineated focal region. The imaging region contains the focal region.
A primer composition, a kit and a method for detecting polymorphic STR markers based on capillary electrophoresis and applications thereof are provided, which are used to simultaneously amplify 13 STR loci on cattle genome. The primer composition includes one or more pairs of primers with sequences as shown in SEQ ID NO: 1˜26. Developmental validation indicated that the kit is of high sensitivity, fine specificity, strong stability and high accuracy. This provides an effective tool for species identification, individual identification and parental analysis of cattle samples in civil disputes and illegal crimes.
Provided is a long-acting method for a coronavirus polypeptide fusion inhibitor. The method comprises coupling an IgG Fc binding peptide to a coronavirus polypeptide therapeutic agent, wherein the coronavirus polypeptide therapeutic agent comprises an amino acid sequence selected from SEQ ID NOs: 1-3, or a variant thereof having substitution, insertion, deletion or addition of one or more amino acids, and the IgG Fc binding peptide comprises an amino acid sequence of SEQ ID NO: 4, or a variant thereof having substitution, insertion, deletion or addition of one or more amino acids. By means of the method, the coronavirus polypeptide therapeutic agent can be long-acting or the effect of the coronavirus polypeptide therapeutic agent is improved.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
90.
β-CATENIN/BCL9 PROTEIN-PROTEIN INTERACTION INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY CO., LTD. (China)
Inventor
Zhu, Di
Zhang, Qingwei
Liu, Chenglong
Zhang, Hao
Li, Jiayi
Chen, Qiushi
Abstract
Provided in the present invention are a β-catenin/BCL9 protein-protein interaction inhibitor, a preparation method therefor and the use thereof. Specifically, the inhibitor provided by the present invention comprises at least one compound or a derivative of said at least one compound. The compound has a novel structure, the structural formula of the compound being any one of formula (I), formula (II), formula (III), formula (IV) and formula (V). The inhibitor of the present invention has the advantages of high pharmacological activity, good safety, good water solubility, good anti-tumor cell proliferation activity, stable in-vitro liver microsome metabolism, etc.
C07D 217/06 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
Disclosed are a novel nanobody (Nb) targeting a tissue factor (TF), and a nanobody-drug conjugate (NDC) and a preparation method therefor and use thereof. The monoclonal Nb and the corresponding NDC of the present invention can effectively and specifically bind to a purified TF protein and TFs on the surface of tumor cells with multiple TF abnormal expressions, have high affinity and low immunogenicity, and have significant in vivo and in vitro anti-tumor effects.
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention provides a pre-embedding agent using organic sulfinate as a framework for pre-embedding lithium or sodium, a pre-embedded lithium positive electrode, a pre-embedded sodium positive electrode, a secondary battery, and a method for pre-embedding lithium or sodium using the pre-embedding agent. The pre-embedding agent of the present invention has a high specific capacity, excellent stability, is free of residues, has excellent compatibility with a battery system, and can be well applied to lithium- or sodium-ion secondary batteries. A pre-embedding process of the method for pre-embedding lithium or sodium of the present invention is safe and convenient, the process is simple, the costs are low, and large-scale production can be achieved.
Disclosed are a new nanobody (Nb) targeting a tissue factor (TF) and a nanobody-drug conjugate (NDC), a preparation method therefor and the use thereof. The monoclonal nanobody and the corresponding NDC can efficiently and high-specifically bind to a purified TF protein and a TF on the surface of various TF abnormally expressed tumor cells, have a high affinity and a low immunogenicity, and have a significant anti-tumor effect in vivo and in vitro.
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 35/04 - Antineoplastic agents specific for metastasis
G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
Provided are a protein or mRNA vaccine against novel coronavirus and a preparation method and a use thereof. The protein has increase, deletions or substitutions of one or more amino acid residues on an amino acid sequence as shown in SEQ ID NO: 59. Also provided is a corresponding nucleic acid that encodes an S protein mutant. Preclinical animal test data shows that the mRNA vaccine has a good protection effect on current mainstream variants of concern (VOC), good stability, and long-lasting efficacy, and has a wide clinical application prospect.
The present invention relates to a photo-response detector, in particular to a ferroelectric field modulated positive and negative photo-response detector, a preparation method and application thereof. The ferroelectric field modulated positive and negative photo-response detector includes a substrate, a gate electrode, a ferroelectric layer, a low-dimensional semiconductor and a source-drain electrode. A pair of gate electrodes are provided and fixedly arranged on the substrate at intervals. The ferroelectric layer is fixedly arranged on the substrate and completely covers the gate electrode. The low-dimensional semiconductor is fixedly arranged on the ferroelectric layer. The source-drain electrode includes a source electrode and a drain electrode separately arranged on two sides of the low-dimensional semiconductor and fixedly arranged on the ferroelectric layer.
G06N 3/06 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons
H01L 31/113 - Devices sensitive to infrared, visible or ultraviolet radiation characterised by field-effect operation, e.g. junction field-effect photo- transistor being of the conductor-insulator- semiconductor type, e.g. metal- insulator-semiconductor field-effect transistor
H01L 31/18 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof
97.
SEGMENTED APERTURE IMAGING AND POSITIONING METHOD OF MULTI-ROTOR UNMANNED AERIAL VEHICLE-BORNE SYNTHETIC APERTURE RADAR
A segmented aperture imaging/positioning method of a multi-rotor unmanned aerial radar. A target echo is acquired based on an unmanned aerial vehicle-borne synthetic aperture radar system. An echo signal estimated from the motion state of a manoeuvring platform is segmented. Motion compensation is performed on each echo signal segment. A two-dimensional spectrum is obtained by performing a two-dimensional Fourier transform on each compensated echo signal segment. A series inversion method to decompose the two-dimensional spectrum is used to obtain a phase filter of each segment. The two-dimensional spectrum of each segment is multiplied by the phase filter, and an image of each segment is obtained by performing two-dimensional inverse Fourier transform on the two-dimensional spectrum. A full-aperture imaging result is obtained by performing geometric corrections on the images and splicing them. The trajectory of each segment of the platform is spliced to obtain complete trajectory coordinates of the platform.
A method for preparing a wafer-scale two-dimensional (2D) material array includes the following steps. Water and alcohol solvent are mixed to obtain a mixed solution. A polydimethylsiloxane (PDMS) stamp with micro posts is prepared. A monolayer two-dimensional transition metal dichalcogenides (2D-TMDs) film is continuously grown on a growth substrate. The PDMS stamp is put upside down to allow the micro posts to adhere to the monolayer 2D-TMDs film, so as to obtain a PDMS stamp-2D-TMDs film-growth substrate combination. The PDMS stamp-2D-TMDs film-growth substrate combination is immersed in the mixed solution to separate the monolayer 2D-TMDs film from the growth substrate. A portion of the monolayer 2D-TMDs film which is not in contact with upper surfaces of the micro posts is removed to obtain a patterned 2D-TMDs film. The patterned 2D-TMDs film is transferred to a target substrate to obtain the wafer-scale 2D material array.
The present application relates to a brain age prediction method based on dual-modality imaging, comprising dual-modality feature fusion. The dual-modality comprises both MRI medical imaging and PET medical imaging; and the feature fusion is obtained on the basis of a 3D convolutional neural network method, and comprises the following steps: extracting features of PET and MRI images by using two 3D convolutional neural networks as backbone networks; concatenating, in a channel dimension, the features of the MRI and PET images extracted by the two backbone networks, and then inputting same into squeeze-and-excitation networks; and multiplying an output result of an excitation part by an original feature map to obtain features of fused channel attention information, and obtaining a fused feature map of dual-modality features.
G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
A protein or mRNA vaccine against novel coronavirus and a preparation method therefor and a use thereof. The protein has addition, deletion or substitution of one or more amino acid residues in an amino acid sequence shown in SEQ ID NO: 2. A nucleic acid encodes an S protein mutant. The preclinical animal test data of the mRNA vaccine shows that the mRNA vaccine has a good protection effect against current novel coronavirus mainstream variants of concern (VOCs).
patents
